3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
2
Other hematologic neoplasm
2
Gastrointestinal
2
Thoracic
1
Sarcoma
1
Lymphoid
1
Head & Neck
1
CNS
1
Conditions
Glioblastoma
3
Gliosarcoma
2
Stomach Neoplasms
1
Sarcoma
1
Neuroblastoma
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Hematologic Neoplasms
1
Glioma
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Brain Neoplasms
1
Interventions
Temozolomide
19
Bevacizumab
14
Irinotecan
12
Carboplatin
10
Cyclophosphamide
9
Radiosurgery
8
Lomustine
8
Radiotherapy
7
pembrolizumab
6
Vincristine
6
Topotecan
6
Drug Therapy
6
Surgical Procedures, Operative
5
Etoposide
5
Doxorubicin
5
Cisplatin
5
3-Iodobenzylguanidine
5
trametinib
4
Metformin
4
Gemcitabine
4
Dexamethasone
4
Blood Specimen Collection
4
poly ICLC
3
dabrafenib
3
Vorinostat
3
Trastuzumab
3
Therapeutics
3
Radiation
3
Paclitaxel
3
Observation
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
capmatinib
×
CNS
×
Clear all
NCT06988475
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled